Thoracoscopic Mesh Repair of Diaphragmatic Defects for Hepatic Hydrothorax

Thoracoscopic Mesh Repair of Diaphragmatic Defects for Hepatic Hydrothorax: 10 Years' Experience From a Single Large-volume Center

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02508688

Enrollment

Registered

2015-07-27

Start date

2005-01-31

Completion date

2015-06-30

Last updated

2015-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Cirrhosis

Keywords

hepatic hydrothorax, thoracoscopic surgery, diaphragmatic defect

Brief summary

The management of refractory hepatic hydrothorax is challenging and usually unsuccessful. The study will discuss the perioperative treatment, effectiveness, and morphology of diaphragmatic defects of hepatic hydrothorax in thoracoscopic mesh repair. Risk factors associated with increased three-month mortality in these critically ill patients will be studied.

Detailed description

Objective The objective was to analyze the outcomes of thoracoscopic mesh repair for hepatic hydrothorax (HH) at the institution of the investigators during the past 10 years. Methods A total of 63 patients with refractory HH, who underwent thoracoscopic mesh onlay reinforcement to repair diaphragmatic defects from January 2005 to December 2014, were included in the study. Mesh covering alone was used in 47 patients and mesh with suturing was used in 16 patients. Patient demographics, Child-Pugh class, and model for end-stage liver disease (MELD) score were evaluated to predict morbidity and mortality.

Interventions

PROCEDUREthoracoscopic diaphragmatic repair

patients with refractory hepatic hydrothorax (\> 3 times thoracentesis and failure to maximal doses of diuretics) who underwent thoracoscopic diaphragmatic repair

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* patients with refractory hepatic hydrothorax (\> 3 times thoracentesis and failure to maximal doses of diuretics)

Exclusion criteria

* Patients with systemic bacteremia, positive culture of bacteria of pleural effusion or ascites were excluded from the study because of potential mesh contamination.

Design outcomes

Primary

Measure	Time frame	Description
one-month mortality	one month	one-month mortality after thoracoscopic mesh repair
three-month mortality	three month	three-month mortality after thoracoscopic mesh repair

Secondary

Measure	Time frame	Description
recurrence of hepatic hydrothorax	20.5 months	recurrence of hepatic hydrothorax after thoracoscopic mesh repair

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026